文献速递临床试验与 GCP基础与转化研究

间歇性衰老细胞清除治疗对绝经后女性骨代谢的影响:一项2期随机对照试验

Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.
PubMed 文献 · Nat Med · 2024-07-02

这项2期随机对照试验在60名绝经后女性中评估间歇性达沙替尼联合槲皮素(D+Q)对骨代谢的影响。主要终点20周时骨吸收标志物CTx百分比变化组间无差异(D+Q中位数-4.1% vs 对照-7.7%,P=0.611);骨形成标志物P1NP在2周和4周显著升高(+16%,P=0.020;+16%,P=0.024),20周时无差异。探索性分析提示高衰老细胞负荷女性骨骼反应更明显,需进一步研究。

要点

  • 间歇性D+Q未降低总体绝经后女性骨吸收(20周CTx变化组间无差异,P=0.611)。
  • D+Q组P1NP在2周和4周较对照显著升高(均+16%),20周时无差异。
  • 探索性分析中高衰老细胞负荷女性D+Q后P1NP升高、CTx降低、桡骨骨密度增加。

核心结论

  • 间歇性D+Q治疗未降低总体绝经后女性的骨吸收。
  • 探索性分析提示基础衰老细胞负荷可能决定临床反应,需进一步研究验证该假说。

研究设计与样本

  • 2期随机对照试验,纳入60名绝经后女性,间歇性给予衰老细胞清除组合达沙替尼加槲皮素(D+Q)。

主要发现

  • 主要终点20周时1型胶原C端肽(CTx)百分比变化组间无差异:D+Q中位数-4.1%(四分位距-13.2,2.6),对照-7.7%(-20.1,14.3),P=0.611。
  • 次要终点1型前胶原N端前肽(P1NP)百分比变化:D+Q组较对照在2周时+16%(P=0.020)、4周时+16%(P=0.024),20周时-9%(P=0.149)无差异。
  • 未观察到严重不良事件。
  • 探索性分析中,骨骼反应主要由T细胞p16(CDKN2A)mRNA水平最高三分位的高衰老细胞负荷女性驱动:2周时P1NP+34%(P=0.035)、CTx-11%(P=0.049),20周时桡骨骨密度+2.7%(P=0.004)。

局限性

  • 原文指出需进一步研究验证基础衰老细胞负荷可能决定衰老细胞清除治疗临床反应这一假说。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preclinical evidence demonstrates that senescent cells accumulate with aging and that senolytics delay multiple age-related morbidities, including bone loss. Thus, we conducted a phase 2 randomized controlled trial of intermittent administration of the senolytic combination dasatinib plus quercetin (D + Q) in postmenopausal women (n = 60 participants). The primary endpoint, percentage changes at 20 weeks in the bone resorption marker C-terminal telopeptide of type 1 collagen (CTx), did not differ between groups (median (interquartile range), D + Q -4.1% (-13.2, 2.6), control -7.7% (-20.1, 14.3); P = 0.611). The secondary endpoint, percentage changes in the bone formation marker procollagen type 1 N-terminal propeptide (P1NP), increased significantly (relative to control) in the D + Q group at both 2 weeks (+16%, P = 0.020) and 4 weeks (+16%, P = 0.024), but was not different from control at 20 weeks (-9%, P = 0.149). No serious adverse events were observed. In exploratory analyses, the skeletal response to D + Q was driven principally by women with a high senescent cell burden (highest tertile for T cell p16 (also known as CDKN2A) mRNA levels) in which D + Q concomitantly increased P1NP (+34%, P = 0.035) and reduced CTx (-11%, P = 0.049) at 2 weeks, and increased radius bone mineral density (+2.7%, P = 0.004) at 20 weeks. Thus, intermittent D + Q treatment did not reduce bone resorption in the overall group of postmenopausal women. However, our exploratory analyses indicate that further studies are needed testing the hypothesis that the underlying senescent cell burden may dictate the clinical response to senolytics. ClinicalTrials.gov identifier: NCT04313634 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Farr JN, Atkinson EJ, Achenbach SJ, et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med. 2024. PMID: 38956196. doi:10.1038/s41591-024-03096-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。